Abstract
Adjuvant cisplatin-based chemotherapy benefits selected patients with stages II and III non-small cell lung cancer (NSCLC). However, carboplatin being tolerated better than cisplatin, carboplatin-based adjuvant therapy may have better chemotherapy compliance. This study aimed to investigate the feasibility and toxicity of adjuvant carboplatin and docetaxel in patients with completely resected locally advanced NSCLC. Eighty patients with completely resected locally advanced NSCLC were enrolled in this trial. Adjuvant chemotherapy was initiated between 1 and 4 weeks after surgery, and consisted of four cycles of carboplatin (AUC=5), and docetaxel (Taxotere, 75mg/m(2)) every 3 weeks, after which patients received prophylactic G-CSF supportive therapy. Patient demographics were: Median age 55 years (range 34-73): gender ratio was 56.3% male/43.7% female: 72.5% of the patients were at stage IIIA and 27.5% were at stage IIIB. The two most common histologies were adenocarcinoma (62.5%) and squamous cell carcinoma (17.5%). Sixty-six patients (82.5%) received four cycles of therapy over a 12-week period. Fourteen patients (17.5%) did not complete therapy due to: patient refusal (n=12), severe adverse events (n=1) and bone metastases dur...Continue Reading
References
Oct 7, 1995·BMJ : British Medical Journal
Jun 1, 1997·Chest·C F Mountain
Feb 7, 2002·Journal of the National Cancer Institute·Corey J LangerDavid H Johnson
Jul 3, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frank FossellaChandra P Belani
Aug 12, 2003·Cancer·Thomas A HensingMark A Socinski
Oct 2, 2003·Journal of the National Cancer Institute·Giorgio V ScagliottiUNKNOWN Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigato
Dec 3, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·I MaestuA Albert
Jan 23, 2004·The New England Journal of Medicine·Rodrigo ArriagadaUNKNOWN International Adjuvant Lung Cancer Trial Collaborative Group
Aug 25, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katsuyuki HottaMitsune Tanimoto
Jun 24, 2005·The New England Journal of Medicine·Timothy WintonUNKNOWN National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators
Sep 2, 2006·The Lancet Oncology·Jean-Yves DouillardPatrick Hurteloup
Apr 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carmela PepeUNKNOWN National Cancer Institute of Canada and Intergroup Study JBR.10
Jun 7, 2007·Journal of the National Cancer Institute·Andrea ArdizzoniUNKNOWN CISCA (CISplatin versus CArboplatin) Meta-analysis Group
Feb 28, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Thomas E StinchcombeMark A Socinski
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Pierre PignonUNKNOWN LACE Collaborative Group
Sep 24, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary M StraussMark R Green
Oct 8, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Si-Yu WangHua Yang
Citations
Dec 4, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Steven M Keller
Oct 7, 1998·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·F TanakaH Wada
Apr 6, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yuping JiaShuntai Chen
Jan 18, 2012·Revista da Associação Médica Brasileira·Riad Naim YounesJefferson Luiz Gross
Jan 23, 2016·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Gerald Schmid-BindertCarla Visseren-Grul
Feb 11, 2011·Current Opinion in Oncology